Lifeng Wang

Lifeng Wang

Auto-generated profile, based on publicly available information

Lifeng Wang

Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Molecular Cell
Verified
Journal Article
Closed access
HWHuayi Wang
Huayi Wang
LSLiming Sun
Liming Sun
LSLijing Su
Lijing Su
JRJosep Rizo
Josep Rizo
LLLei Liu
Lei Liu
XWXiaodong Wang
Xiaodong Wang

25 July 2015 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
LWLifeng Wang
Lifeng Wang
FWFusheng Wang
Fusheng Wang
MGM. Eric Gershwin
M. Eric Gershwin
There have been significant advances in our understanding of human autoimmunity that have led to improvements in classification and diagnosis and, most importantly, research advances in new therapies. The importance of autoimmunity and the mechanisms that lead to clinical disease were first recognized about 50 years ago following the pioneering studies of Macfarlane Burnett and his Nobel Prize‐winning hypothesis of the ‘forbidden clone’. Such pioneering efforts led to a better understanding not only of autoimmunity, but also of lymphoid cell development, thymic education, apoptosis and deletion of autoreactive cells. Contemporary theories suggest that the development of an autoimmune disease requires a genetic predisposition and environmental factors that trigger the immune pathways that lead, ultimately, to tissue destruction. Despite extensive research, there are no genetic tools that can be used clinically to predict the risk of autoimmune disease. Indeed, the concordance of autoimmune disease in identical twins is 12–67%, highlighting not only a role for environmental factors, but also the potential importance of stochastic or epigenetic phenomena. On the other hand, the identification of cytokines and chemokines, and their cognate receptors, has led to novel therapies that block pathological inflammatory responses within the target organ and have greatly improved the therapeutic effect in patients with autoimmune disease, particularly rheumatoid arthritis. Further advances involving the use of multiplex platforms for diagnosis and identification of new therapeutic agents should lead to major breakthroughs within the next decade.

1 August 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
YSYing Sun
Ying Sun
YDYanli Dong
Yanli Dong
LWLifeng Wang
Lifeng Wang
HXHuan Xie
Huan Xie
BLBaosen Li
Baosen Li
FWFusheng Wang
Fusheng Wang

15 July 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
LWLifeng Wang
Lifeng Wang
JLJin Li
Jin Li
HLHonghong Liu
Honghong Liu
YLYuanyuan Li
Yuanyuan Li
JFJunliang Fu
Junliang Fu
FWFusheng Wang
Fusheng Wang
Background and Aim: graphic Ursodeoxycholic acid (UDCA) treatment is an effective medical therapy for patients with primary biliary cirrhosis (PBC); however, 40% of PBC patients show an incomplete response to the UDCA therapy. This study aimed to investigate the safety and efficacy of umbilical cord‐derived mesenchymal stem cell (UC‐MSC) transfusion in PBC patients with an incomplete response to UDCA.Methods: We conducted a single‐arm trial that included seven PBC patients with a suboptimal response to UDCA treatment. UC‐MSCs were first cultured, and then 0.5 × 106 cells/kg body weights were infused through a peripheral vein. UC‐MSCs were given three times at 4‐week intervals, and patients were followed up for 48 weeks. Primary outcomes were to evaluate the safety and feasibility of UC‐MSC treatment, and secondary outcomes were to evaluate liver functions and patient's quality of life.Results: No obvious side‐effects were found in the patients treated with UC‐MSCs. Symptoms such as fatigue and pruritus were obviously alleviated in most patients after UC‐MSC treatment. There was a significant decrease in serum alkaline phosphatase and γ‐glutamyltransferase levels at the end of the follow‐up period as compared with baseline. No significant changes were observed in serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, prothrombin time activity, international normalized ratio, or immunoglobulin M levels. The Mayo risk score, a prognostic index, was also stable during the treatment and follow‐up period.Conclusions: UC‐MSC transfusion is feasible and well tolerated in patients with PBC who respond only partially to UDCA treatment, thus representing a novel therapeutic approach for patients in this subgroup. A larger, randomized controlled cohort study is warranted to confirm the clinical efficacy of UC‐MSC transfusion.

1 April 2022 in Food Chemistry
Verified
Journal Article
Closed access
XHXintian Hu
Xintian Hu
FXFeiran Xu
Feiran Xu
JLJinglei Li
Jinglei Li
JLJun Li
Jun Li
CMCheng Mo
Cheng Mo
LWLifeng Wang
Lifeng Wang

29 November 2021 in Hepatology International
Verified
Journal Article
Open access
PDF file
MSMing Shi
Ming Shi
YLYuan-Yuan Li
Yuan-Yuan Li
RXRuo-Nan Xu
Ruo-Nan Xu
FMFanping Meng
Fanping Meng
SYShuang-Jie Yu
Shuang-Jie Yu
FWFusheng Wang
Fusheng Wang
Background: Mesenchymal stem cell (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is poorly understood. Methods: This prospective, open-labeled, randomized controlled study enrolled 219 patients with HBV-related DLC who were divided into control group (n = 111) and umbilical cord-derived MSC (UC-MSC)-treated group (n = 108), then all of them received a follow-up check from October 2010 to October 2017. The treated patients received three times of UC-MSC infusions at 4-week intervals plus conventional treatment that was only used for control group. The overall survival rate and HCC-free survival rate were calculated as primary endpoints and the liver function and adverse events associated with the medication were also evaluated. Results: During the follow-up check period from 13 to 75th months, there was a significantly higher overall survival rate in the treated group than the control group, while the difference of the hepatocellular carcinoma event-free survival rate between the treated and control groups was not observed during the 75-month follow-up. UC-MSC treatment markedly improved liver function, as indicated by the levels of serum albumin, prothrombin activity, cholinesterase, and total bilirubin during 48 weeks of follow-up. No significant side effects or treatment-related complications were observed in the UC-MSC group. Conclusions: Therapy of UC-MSC is not only well tolerated, but also significantly improves long-term survival rate, as well as the liver function in patients with HBV-related DLC. UC-MSC medication, therefore, might present a novel therapeutic approach for the disease. Graphic